Poly Medicure (531768) Investor presentation summary
Event summary combining transcript, slides, and related documents.
Investor presentation summary
9 Mar, 2026Platform overview and global reach
Operates in 125+ countries with 15 manufacturing plants across 5 countries and a 1.8 billion+ annual device capacity.
Holds 390+ patents and has 950+ distributors and 570+ sales associates globally.
Largest exporter of consumable medical devices for 10 consecutive years.
Innovation, R&D, and product pipeline
100+ R&D professionals and 30+ new product launches annually, with 100+ products in the development pipeline.
390+ patents granted, with strong in-house tooling, automation, and rapid prototyping capabilities.
Plans to double R&D spending in the coming years.
Strategic acquisitions and portfolio expansion
Acquired Plan Health, Pendracare, and Citieffe, expanding into cardiology and orthopaedics.
Post-acquisition, Plan Health grew at 20% CAGR with improved margins; Citieffe and Pendracare added significant revenue and EBITDA.
Focused on expanding trauma, cardiology, and orthopaedics portfolios, including new launches and clinical trials.
Latest events from Poly Medicure
- Q2 revenue up 5.7% YoY; FY26 growth guided at 15%-16% with margins at 25%-27%.531768
Q2 25/269 Jul 2026 - Strong H1 FY25 revenue and profit growth, driven by QIP-funded expansion and robust exports.531768
Q2 24/258 Jul 2026 - Q1 FY26 saw robust revenue and profit growth, innovation, and strategic expansion.531768
Q1 25/268 Jul 2026 - Strategic shift and acquisitions drove 12.3% revenue growth, margin gains, and a ₹3.5 dividend.531768
Q4 25/2627 May 2026 - Double-digit revenue growth and margin strength driven by expansion and innovation.531768
Q3 25/266 Feb 2026 - Q3 FY25 revenue up 24.9% YoY, margins and cash position strong, growth outlook robust.531768
Q3 24/253 Feb 2026 - Q1 revenue and EBITDA up 20%, EPS rises, exports surge, and capacity expansion drives growth.531768
Q1 24/253 Feb 2026 - FY25 revenue rose 21.5% with margin gains, QIP capital raised, and a ₹3.50 dividend recommended.531768
Q4 24/257 Jan 2026 - Acquisition accelerates global orthopaedics expansion with strong product and market synergies.531768
M&A Announcement25 Sep 2025